CLOV

SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or “Clover Health”), and a leading AI-powered physician enablement platform, today released findings within the whitepaper  “Clinical Excellence in Continuity of Care: A Real-World Analysis of Counterpart Assistant's Role in Post-Hospitalization Follow-up.” The whitepaper examines the relationship between CA use by primary care physicians (“PCPs”) and performance on high-risk care transition outcomes, including two HEDIS®1 quality measures within Clover Health's Medicare Advantage population: Transitions of Care (“TRC”) and Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (“FMC”).

CEO Andrew Toy sold 313,476 shares of Common Stock for a transaction value of ~$1.67 million as of July 1, 2026. This transaction represented 3.16% of Toy's direct holdings, reducing direct ownership to 9,609,825 shares.

Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript

Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-leading Medicare Advantage membership growth with underlying trends tracking in line with expectations Expect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-year First quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-year First quarter 2026 Consolidated Gross Profit of $160 million, up 47% year-over-year, and Adjusted EBITDA of $40 million, up 56% year-over-year Full Year 2026 Guidance: Average Medicare Advantage membership of 154,000 - 158,000, representing 46% growth year-over-year at the midpoint Total revenues between $2.81 billion and $2.92 billion, representing 49% growth year-over-year at the midpoint Consolidated Gross Profit between $470 million and $510 million, representing 38% growth year-over-year at the midpoint Adjusted EBITDA profitability between $50 million and $70 million GAAP Net Income between $0 million and $20 million WILMINGTON, Del., May 06, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the first quarter 2026.

Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.06 per share a year ago.

CLOV rides strong membership growth and an AI-driven care model, but rising costs and policy risks cloud the near-term outlook.

WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026.

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, in partnership with  HealthEx , today announced a new collaboration that enables Clover Medicare Advantage (MA) members to securely access and share clinical records and claims data, further advancing patients rights to access and share their own health data, which is central to federal interoperability efforts.